Latest & greatest articles for nsaids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nsaids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nsaids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nsaids

101. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK Jansen J P, Pellissier J, Choy E H, Ostor A, Nash J T, Bacon P, Hunsche E Record Status This is a critical abstract of an economic evaluation that meets (...) acknowledged the limitations of their study in their discussion. Concluding remarks: Overall the methodology of the study was adequate and the methods and results were well reported. Given the scope of the analysis, the author’s conclusions appear to be valid. Funding Funded by Merck & Co., Inc. Bibliographic details Jansen J P, Pellissier J, Choy E H, Ostor A, Nash J T, Bacon P, Hunsche E. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK

2007 NHS Economic Evaluation Database.

102. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review

Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline (...) Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review Delia Schaffer, Timothy Florin, Craig Eagle, Ian Marschner, Gurkirpal Singh, Mendel Grobler, Chris Fenn, Manjula Schou and Kathleen M Curnow Med J Aust 2006; 185 (9): 501-506. || doi: 10.5694/j.1326-5377.2006.tb00665.x Published online: 6 November 2006 Topics Abstract Objective: N on-selective non-steroidal

2006 EvidenceUpdates

103. Intravenous NSAID's in the Management of Renal Colic

Intravenous NSAID's in the Management of Renal Colic BestBets: Intravenous NSAID's in the Management of Renal Colic Intravenous NSAID's in the Management of Renal Colic Report By: Debasis Das - SHO Urology Search checked by Stuart Teece - Research Fellow, MRI Institution: Guy's and St. Thomas' Hospital Date Submitted: 5th January 2006 Date Completed: 1st March 2006 Last Modified: 5th January 2006 Status: Green (complete) Three Part Question [In patients presenting with suspected renal colic (...) of prostaglandins which subsequently stimulate pain. While opiates can offer pain relief by subduing patients' awareness of these stimuli, NSAID's can actually treat the pathophysiological mechanisms that cause them in the first place. You wonder whether they would be more effective at providing analgesia? Search Strategy Medline database using Ovid interface: 1966–November 2005. The Cochrane Database of Systematic Reviews was also searched. {{{(exp Injections, Intravenous/ or intravenous. mp.) AND {(exp

2006 BestBETS

104. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review

Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M, Fenn C, Schou M, Curnow K M CRD summary This review investigated whether the occurrence of serious gastrointestinal events decrease (...) over time in studies of long-term use of non-steroidal anti-inflammatory drugs (NSAIDs). The authors found that the probability of having a serious NSAID-related ulcer bleed, perforation or hospitalisation did not meaningfully decline over time. The use of meta-regression with few studies implies cautious interpretation of these results. Authors' objectives To assess whether the occurrence of serious gastrointestinal (GI) events reduces over time in studies of long-term use of non-steroidal anti

2006 DARE.

105. Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs

Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs Article Text

2006 Evidence-Based Medicine (Requires free registration)

106. Review: topical NSAIDs reduce pain in osteoarthritis only during the first 2 weeks of use

Review: topical NSAIDs reduce pain in osteoarthritis only during the first 2 weeks of use Review: topical NSAIDs reduce pain in osteoarthritis only during the first 2 weeks of use | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: topical NSAIDs reduce pain in osteoarthritis only during the first 2 weeks of use Article Text Treatment Review: topical NSAIDs reduce pain in osteoarthritis only during the first 2 weeks of use Free Cathy R

Full Text available with Trip Pro

2006 Evidence-Based Mental Health

107. Review: paracetamol reduces pain in osteoarthritis but is less effective than NSAIDs

Review: paracetamol reduces pain in osteoarthritis but is less effective than NSAIDs Review: paracetamol reduces pain in osteoarthritis but is less effective than NSAIDs | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: paracetamol reduces pain in osteoarthritis but is less effective than NSAIDs Article Text Treatment Review: paracetamol reduces pain in osteoarthritis but is less effective than NSAIDs Free Cathy R Kessenich , RN, DSN

Full Text available with Trip Pro

2006 Evidence-Based Mental Health

108. NSAID-analgesia, pain control and morbidity in cardiothoracic surgery

NSAID-analgesia, pain control and morbidity in cardiothoracic surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

109. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience

A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

110. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs

Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

111. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. (PubMed)

NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. NSAIDs are widely applied to treat cancer pain and are frequently combined with opioids in combination preparations for this purpose. However, it is unclear which agent is most clinically efficacious for relieving cancer-related pain, or even what may be the additional benefit of combining an NSAID with an opioid in this setting.To assess the effects of NSAIDs, alone or combined with opioids, for the treatment of cancer (...) pain.We searched the Cochrane Central Register of Controlled Trials (Issue 2, 2002), MEDLINE (January 1966 to March 2003), EMBASE (January 1980 to December 2001), LILACS (January 1984 to December 2001) and reference list of articles.Randomized controlled trials and controlled clinical trials that compared NSAID versus placebo; NSAID versus NSAID; NSAID versus NSAID plus opioid; opioid versus opioid plus NSAID; or NSAID versus opioid.Two reviewers independently assessed trial quality and extracted data

2005 Cochrane

112. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis

Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors (...) in the treatment of rheumatoid arthritis Yun H R, Bae S C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of non-steroidal anti-inflammatory agents (NSAIDs) with and without concomitant therapy to prevent

2005 NHS Economic Evaluation Database.

113. Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies

Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

114. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

115. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S Record Status (...) was derived from a synthesis of completed studies. Modelling A decision tree model was used to assess the expected costs and consequences of ETO, compared with different options of non-selective NSAIDs, in a hypothetical cohort of 10,000 patients. GI events, major (clinically evident gastroduodenal perforations, symptomatic gastroduodenal ulcers or upper GI bleeding) and minor (those that could lead to treatment), were calculated and entered into the model to derive the total costs associated with each

2004 NHS Economic Evaluation Database.

116. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs

Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs Henry D, McGettigan P CRD summary This review assessed the risk of serious gastrointestinal complications with non-steroidal anti-inflammatory drugs (NSAIDs). The authors concluded that, at low doses, the risk is lower with ibuprofen than with other NSAIDs. Wide variation (...) in the estimate of risk between different studies of the same drugs, which the authors were unable to explain, casts doubt on the reliability of the conclusion. Authors' objectives The objectives were three-fold: to update previous systematic reviews; to determine the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of serious gastrointestinal complications; and to examine the place of drug dose in explaining the variation in this risk. Searching MEDLINE, EMBASE, the Cochrane Library

2003 DARE.

117. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review

Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review Hyllested M, Jones S, Pedersen J L, Kehlet H Authors' objectives To compare the safety and efficacy of paracetamol, non-steroidal anti (...) -inflammatory drugs (NSAIDs), and their combinations in post-operative pain management. Searching MEDLINE (from 1966 to January 2001) and the Cochrane Library (January 2001) were searched for articles published in full in the English language. The search strategy used pain terms combined with the keywords 'paracetamol', 'acetaminophen', 'proparacetamol', 'non-steroidal anti-inflammatory drugs (NSAID)', or individual drug names. The reference lists from identified studies were also examined. Study selection

2002 DARE.

118. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors Zhao S Z, Burke T A, Whelton A, von Allmen H (...) (NSAIDS). No further details of the drugs (producer), or the doses used, were reported. Celecoxib was the comparator. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with stable hypertension who had recently begun therapy with celecoxib, rofecoxib, ibuprofen, diclofenac, or naproxen. Eligible patients were those who had not filled a prescription for a non-specific NSAID or COX-2-specific inhibitor within

2002 NHS Economic Evaluation Database.

119. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis

Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis Fendrick A M, Bandekar R R, Chernew M E, Scheiman J M Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of NSAID gastropathy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The hypothetical population comprised long-term users of NSAIDs without risk factors

2002 NHS Economic Evaluation Database.

120. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective

Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Marshall J K, Pellissier J M, Attard C L, Kong S X, Marentette M (...) published over a number of years. The price year was 1999. Source of effectiveness data The effectiveness evidence came from a review of the literature and authors' assumptions. Modelling A decision tree model was constructed to compare the costs and benefits of the two alternative treatments reflecting practice in the Canadian setting. The model referred to a hypothetical cohort of patients with OA who were treated with either rofecoxib or NSAIDs over a period of one year. Patients could develop GI

2001 NHS Economic Evaluation Database.